NVO ▲ +1.1% - Novo Nordisk A/S $NVO Novo Nordisk: CagriSema Achieves 25% Average Weight Loss in Women in REDEFINE 1 Post-Hoc Analysis ? • Investigational CagriSema 2.4 mg/2.4 mg showed an average 25% weight reduction among female participants. • Findings come from a post-hoc analysis of the REDEFINE 1 trial. 20-OCT-2026 08:37 AM ET